Director/PDMR Shareholding

RNS Number : 6484D

GlaxoSmithKline PLC

20 February 2020

 

GlaxoSmithKline plc (the 'Company')

 Transaction notification

1.	Details of PDMR/person closely associated with them ('PCA')
a)	Name	Ms E Walmsley
b)	Position/status	Chief Executive Officer
c)	Initial notification/ amendment	Initial notification
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	GlaxoSmithKline plc
b)	LEI	5493000HZTVUYLO1D793
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)	Description of the financial instrument	Ordinary shares of 25 pence each ('Ordinary Shares') ISIN: GB0009252882
b)	Nature of the transaction	The exercise of nil-cost options over Ordinary Shares granted on 15 February 2017 under the Company's 2009 Deferred Annual Bonus Plan - Deferred Bonus and Matching Awards.
c)	Price(s) and volume(s)		Price(s)	Volume(s)
			£0.00	37,221 (Deferred)
			£0.00	24,815 (Matching)
d)	Aggregated information	N/A (single transaction)
	Aggregated volume Price	62,036 £0.00
e)	Date of the transaction	2020-02-17
f)	Place of the transaction	N/A

1.	Details of PDMR/person closely associated with them ('PCA')
a)	Name	Ms E Walmsley
b)	Position/status	Chief Executive Officer
c)	Initial notification/ amendment	Initial notification
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	GlaxoSmithKline plc
b)	LEI	5493000HZTVUYLO1D793
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)	Description of the financial instrument	Ordinary shares of 25 pence each ('Ordinary Shares') ISIN: GB0009252882
b)	Nature of the transaction	The sale of Ordinary Shares to meet tax liabilities on the exercise of nil-cost options under the Company's Deferred Annual Bonus Plan - Deferred Bonus and Matching Awards.
c)	Price(s) and volume(s)		Price(s)	Volume(s)
			£16.614	17,523 (Deferred)
			£16.614	11,680 (Matching)
d)	Aggregated information	N/A (single transaction)
	Aggregated volume Price	29,203 £16.614
e)	Date of the transaction	2020-02-17
f)	Place of the transaction	London Stock Exchange (XLON)

1.	Details of PDMR/person closely associated with them ('PCA')
a)	Name	Mr R Connor
b)	Position/status	President, Global Vaccines
c)	Initial notification/ amendment	Initial notification
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	GlaxoSmithKline plc
b)	LEI	5493000HZTVUYLO1D793
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)	Description of the financial instrument	Ordinary shares of 25 pence each ('Ordinary Shares') ISIN: GB0009252882
b)	Nature of the transaction	The exercise of nil-cost options over Ordinary Shares granted on 15 February 2017 under the Company's 2009 Deferred Annual Bonus Plan - Deferred Bonus and Matching Awards.
c)	Price(s) and volume(s)		Price(s)	Volume(s)
			£0.00	19,375 (Deferred)
			£0.00	12,917 (Matching)
d)	Aggregated information	N/A (single transaction)
	Aggregated volume Price	32,292 £0.00
e)	Date of the transaction	2020-02-17
f)	Place of the transaction	N/A

1.	Details of PDMR/person closely associated with them ('PCA')
a)	Name	Mr R Connor
b)	Position/status	President, Global Vaccines
c)	Initial notification/ amendment	Initial notification
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	GlaxoSmithKline plc
b)	LEI	5493000HZTVUYLO1D793
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)	Description of the financial instrument	Ordinary shares of 25 pence each ('Ordinary Shares') ISIN: GB0009252882
b)	Nature of the transaction	The sale of Ordinary Shares to meet tax liabilities on the exercise of nil-cost options over Ordinary Shares under the Company's Deferred Annual Bonus Plan - Deferred Bonus and Matching Awards.
c)	Price(s) and volume(s)		Price(s)	Volume(s)
			£16.714	9,120 (Deferred)
			£16.714	6,081 (Matching)
d)	Aggregated information
	Aggregated volume Price	15,201 £16.714
e)	Date of the transaction	2020-02-17
f)	Place of the transaction	London Stock Exchange (XLON)

1.	Details of PDMR/person closely associated with them ('PCA')
a)	Name	Mr N Hirons
b)	Position/status	SVP, Global Ethics and Compliance
c)	Initial notification/ amendment	Initial notification
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	GlaxoSmithKline plc
b)	LEI	5493000HZTVUYLO1D793
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)	Description of the financial instrument	Ordinary shares of 25 pence each ('Ordinary Shares') ISIN: GB0009252882
b)	Nature of the transaction	The exercise of nil-cost options over Ordinary Shares granted on 15 February 2017 under the Company's 2009 Deferred Annual Bonus Plan - Deferred Bonus and Matching Awards.
c)	Price(s) and volume(s)		Price(s)	Volume(s)
			£0.00	12,243 (Deferred)
			£0.00	8,163 (Matching)
d)	Aggregated information	N/A (single transaction)
	Aggregated volume Price	20,406 £0.00
e)	Date of the transaction	2020-02-17
f)	Place of the transaction	N/A

1.	Details of PDMR/person closely associated with them ('PCA')
a)	Name	Mr N Hirons
b)	Position/status	SVP, Global Ethics and Compliance
c)	Initial notification/ amendment	Initial notification
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	GlaxoSmithKline plc
b)	LEI	5493000HZTVUYLO1D793
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)	Description of the financial instrument	Ordinary shares of 25 pence each ('Ordinary Shares') ISIN: GB0009252882
b)	Nature of the transaction	The sale of Ordinary Shares to meet tax liabilities on the exercise of nil-cost options over Ordinary Shares under the Company's Deferred Annual Bonus Plan - Deferred Bonus and Matching Awards.
c)	Price(s) and volume(s)		Price(s)	Volume(s)
			£16.678	5,770 (Deferred)
			£16.678	3,846 (Matching)
d)	Aggregated information
	Aggregated volume Price	9,616 £16.678
e)	Date of the transaction	2020-02-17
f)	Place of the transaction	London Stock Exchange (XLON)

1.	Details of PDMR/person closely associated with them ('PCA')
a)	Name	Mr B McNamara
b)	Position/status	CEO, GSK Consumer Healthcare
c)	Initial notification/ amendment	Initial notification
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	GlaxoSmithKline plc
b)	LEI	5493000HZTVUYLO1D793
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)	Description of the financial instrument	American Depositary Shares ('ADSs') ISIN: US37733W1053
b)	Nature of the transaction	The sale of ADSs to meet tax liabilities on the vesting of awards under the Company's Deferred Annual Bonus Plan - Deferred Bonus and Matching Awards.
c)	Price(s) and volume(s)		Price(s)	Volume(s)
			$43.544	3,467 (Deferred)
			$43.544	2,423 (Matching)
d)	Aggregated information	N/A (single transaction)
	Aggregated volume Price	5,890 $43.544
e)	Date of the transaction	2020-02-18
f)	Place of the transaction	New York Stock Exchange (XNYS)

1.	Details of PDMR/person closely associated with them ('PCA')
a)	Name	Mr D Redfern
b)	Position/status	Chief Strategy Officer
c)	Initial notification/ amendment	Initial notification
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	GlaxoSmithKline plc
b)	LEI	5493000HZTVUYLO1D793
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)	Description of the financial instrument	Ordinary shares of 25 pence each ('Ordinary Shares') ISIN: GB0009252882
b)	Nature of the transaction	The exercise of nil-cost options over Ordinary Shares granted on 15 February 2017 under the Company's 2009 Deferred Annual Bonus Plan - Deferred Bonus and Matching Awards.
c)	Price(s) and volume(s)		Price(s)	Volume(s)
			£0.00	15,407 (Deferred)
			£0.00	10,273 (Matching)
d)	Aggregated information
	Aggregated volume Price	25,680 £0.00
e)	Date of the transaction	2020-02-17
f)	Place of the transaction	N/A

1.	Details of PDMR/person closely associated with them ('PCA')
a)	Name	Mr D Redfern
b)	Position/status	Chief Strategy Officer
c)	Initial notification/ amendment	Initial notification
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	GlaxoSmithKline plc
b)	LEI	5493000HZTVUYLO1D793
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)	Description of the financial instrument	Ordinary shares of 25 pence each ('Ordinary Shares') ISIN: GB0009252882
b)	Nature of the transaction	The sale of Ordinary Shares to meet tax liabilities on the exercise of nil-cost options over Ordinary Shares under the Company's Deferred Annual Bonus Plan - Deferred Bonus and Matching Awards.
c)	Price(s) and volume(s)		Price(s)	Volume(s)
			£16.629	7,261 (Deferred)
			£16.629	4,840 (Matching)
d)	Aggregated information	N/A (single transaction)
	Aggregated volume Price	12,101 £16.629
e)	Date of the transaction	2020-02-17
f)	Place of the transaction	London Stock Exchange (XLON)

1.	Details of PDMR/person closely associated with them ('PCA')
a)	Name	Mr P Thomson
b)	Position/status	President, Global Affairs
c)	Initial notification/ amendment	Initial notification
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	GlaxoSmithKline plc
b)	LEI	5493000HZTVUYLO1D793
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)	Description of the financial instrument	Ordinary shares of 25 pence each ('Ordinary Shares') ISIN: GB0009252882
b)	Nature of the transaction	The exercise of nil-cost options over Ordinary Shares granted on 15 February 2017 under the Company's 2009 Deferred Annual Bonus Plan - Deferred Bonus and Matching Awards.
c)	Price(s) and volume(s)		Price(s)	Volume(s)
			£0.00	7,302 (Deferred)
			£0.00	4,869 (Matching)
d)	Aggregated information
	Aggregated volume Price	12,171 £0.00
e)	Date of the transaction	2020-02-17
f)	Place of the transaction	N/A

1.	Details of PDMR/person closely associated with them ('PCA')
a)	Name	Mr P Thomson
b)	Position/status	President, Global Affairs
c)	Initial notification/ amendment	Initial notification
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	GlaxoSmithKline plc
b)	LEI	5493000HZTVUYLO1D793
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)	Description of the financial instrument	Ordinary shares of 25 pence each ('Ordinary Shares') ISIN: GB0009252882
b)	Nature of the transaction	The sale of Ordinary Shares to meet tax liabilities on the exercise of nil-cost options over Ordinary Shares under the Company's Deferred Annual Bonus Plan - Deferred Bonus and Matching Awards.
c)	Price(s) and volume(s)		Price(s)	Volume(s)
			£16.623	3,442 (Deferred)
			£16.623	2,294 (Matching)
d)	Aggregated information	N/A (single transaction)
	Aggregated volume Price	5,736 £16.623
e)	Date of the transaction	2020-02-17
f)	Place of the transaction	London Stock Exchange (XLON)

 

END

 

 

DSHXBLFLBLLEBBQ